The ADC binds TROP2 on tumor cells, is internalized, and releases deruxtecan that inhibits topoisomerase I, causing DNA damage and apoptosis; topoisomerase I is the payload’s enzyme target, not the recognition target, so its expression alone does not trigger selective killing.